As biologics portfolios expand, identity testing has shifted from a regulatory checkbox to a mission-critical manufacturing risk — and the tools to manage it have never been more capable. (more…)

Lateral flow assays (LFA) and enzyme-linked immunosorbent assays (ELISA) are widely used immunoassay techniques. Choosing the right method depends on application, sensitivity, and environment. Both methods have been around for over 50 years, and each has earned a well-deserved place in diagnostics. But they are not interchangeable — ELISA offers high sensitivity, while LFA provides rapid results. Understanding where each excels is critical to selecting the right tool for your application. (more…)

In lateral flow assay (LFA) development, new label technologies emerge every year. While it’s tempting to assume they offer an edge, in reality, most diagnostics teams racing to prototype, validate, and commercialize an assay don’t need more complexity. They need consistency, scalability, and a material that works reliably across many assay formats and manufacturing environments. (more…)

In the fast-evolving world of diagnostics and biotechnologies, time-to-market is everything. For companies of all sizes—whether resource-rich or resource-limited—contract assay developers offer a path to faster timelines, reduced risk, and expert guidance. (more…)